¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"familial high-density lipoprotein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • familial goiter
    °¡Á·¼º°©»ó»ùÁ¾
  • familial hemophagocytic lymphohistiocytosis
    °¡Á·¼ºÀûÇ÷±¸Æ÷½Ä¼º¸²ÇÁÁ¶Á÷±¸Áõ½ÄÁõ
  • familial paroxysmal polyserositis
    °¡Á·¼º¹ßÀÛ´Ù¹ßÀ帷¿°
  • familial polyposis
    °¡Á·¼ºÆú¸³Áõ
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • familial tremor
    °¡Á·¼º¶³¸²
  • idiopathic familial fibromatosis
    Ư¹ß°¡Á·¼¶À¯Á¾Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • familial adenomatous polyposis
    °¡Á·»ùÁ¾Æú¸³Áõ
  • familial paroxysmal polyserositis
    °¡Á·¹ßÀÛ´Ù¹ßÀ帷¿°
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • idiopathic familial fibromatosis
    Ư¹ß°¡Á·¼¶À¯Á¾Áõ
  • transient familial neonatal hyperbilirubinemia
    Àϰú¼º°¡Á·½Å»ý¾Æ°íºô¸®·çºóÇ÷Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hyperbilirubinemia,asymptomatric familial
    ¹«ÁõÈÄ °¡Á·¼º(Ùíñøý¦ Ê«ðéàõ)
  • hypercholesterolemia,familial
    °¡Á·¼º(Ê«ðéàõ)
  • idiopathic familial fibromatosis
    Ư¹ß¼º °¡Á·¼º ¼¶À¯Á¾Áõ.
  • idiopathic familial fibromatosis
    Ư¹ß¼º °¡Á·¼º ¼¶À¯Á¾Áõ
  • infantile amaurotic familial idiocy
    ¿µ¾Æ¼º Èæ³»À强 °¡Á·¼º ¹éÄ¡.
  • infantile amaurotic familial idiocy
    ¿µ¾Æ¼º Èæ³»À强 °¡Á·¼º ¹éÄ¡.
  • plasma lipoprotein abnormalities
    Ç÷ÀåÁöÁú´Ü¹éÁúÀÌ»óÁõ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low density lipoprotein
    Àú¹ÐµµÁö´Ü¹é
  • low density lipoprotein =LDL
    Àú¹ÐµµÁö´Ü¹é.
  • low density lipoprotein =LDL
    Àú¹ÐµµÁö´Ü¹éÁú.
  • plasma lipoprotein abnormalities
    Ç÷ÀåÁöÁú´Ü¹éÁúÀÌ»óÁõ.
  • very low density lipoprotein
    ±ØÀúºñÁßÁö´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁö´Ü¹é(Áú)
  • very low density lipoprotein =VLDL
    ÃÊÀúºñÁßÁö(Áú)´Ü¹é(Áú).
  • very low-density lipoprotein =VLDL
    ÃÊÀú¹ÐµµÁö(Áú)´Ü¹é(Áú).
  • amaurotic familial idiocy =Tay-Sachs disease
    °¡Á·¼º Èæ³»Àå ¹éÄ¡(Ê«ðéàõýÙÒ®î¡ÛÜöÁ).
  • amaurotic familial idiocy =Tay-Sachs disease
    °¡Á·¼ºÈæ¾Ï½Ã¹éÄ¡(Ê«ðéàõýÙÒ®î¡ÛÜöÁ).
  • benign familial pemphigus
    ¾ç¼º °¡Á·¼º(åÐàõ Ê«ðéàõ) õÆ÷â(ô¸øÞóê)
  • breast/ovarian familial cancer syndrome
    À¯¹æ/³­¼Ò °¡Á·¼º ¾ÏÁõÈıº
  • chronic familial jaundice
    ¸¸¼º°¡Á·¼º Ȳ´Þ(¡­Ê«ðéàõüÜÓ¸).
  • diffuse familial comedo
    ±¤¹üÀ§ °¡Á·¼º ¸éÆ÷
  • dysbetalipoproteinemia.familial
    °¡Á·¼ºÀÌ»óº£Å¸¸®Æ÷ÇÁ·ÎÅ×ÀÎÇ÷Áõ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • very low-density lipoprotein
    ÃÊÀú¹Ðµµ (õ±î¸ÚËÓø) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • very low-lipid lipoprotein
    ÃÊÀúÁöÁú(õ±î¸ò·òõ) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LDL Low Density Lipoprotein; Àú¹Ðµµ ÁöÁú ´Ü¹éÁú
VLDL Very Low Density Lipoprotein
BLP beta-lipoprotein
B-LPH beta-lipoprotein hormone
HDL high-density lipoprotein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FAP Familial Amyloid Polyneuropathy
FAP Familial Amyloidotic Polyneuropathy
FALS Familial Amyotrophic Lateral Sclerosis
FATS Familial Atherosclerosis Treatment Study
FCH Familial Combined Hyperlipidaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • familial fibrous dysplasia
    °¡Á·¼º ¼¶À¯ ÀÌÇü¼º
  • familial genuine malfomation of root
    °¡Á·¼º ¼±Ãµ¼º Ä¡±Ù ±âÇü
    µ¿ÀǾî=dentinal dys
  • familial hemolytic anemia
    °¡Á·¼º ¿ëÇ÷¼º ºóÇ÷
  • familial histocytic dermatoarthritis
    °¡Á·¼º Á¶Á÷±¸¼º ÇǺΠ°üÀý¿°
  • familial hyperlipoproteinemia
    °¡Á·¼º °úÁöÁú´Ü¹éÇ÷Áõ
  • familial hypophosphatemic rickets

    familial leiomyomatosis cutis et uteri (°¡Á·¼º ÇǺΠÀڱà ±ÙÁ¾Áõ

  • familial Mediterranean fever
    °¡Á·¼º ÁöÁßÇØ ¿­
  • familial neutropenia
    °¡Á·¼º È£Áß±¸ °¨¼ÒÁõ
  • familial polyposis
    °¡Á·¼º Æú¸³Áõ
  • familial progressive sensorineural hearing loss
    °¡Á·¼º ÁøÇ༺ °¨°¢ ½Å°æ¼º ³­Ã»
  • familial teleangiectasis
    °¡Á·¼º ¸»ÃÊÇ÷°ü È®Àå, °¡Á·¼º ¸»ÃÊÇ÷°ü È®ÀåÁõ
  • fatal familial insomnia
    Ä¡¸íÀû °¡Á·¼º ºÒ¸éÁõ
    ºÒ¸éÁõ°ú ÀÚÀ²½Å°æ Àå¾Ö°¡ ÁÖ Áõ»óÀÌ°í ¸ðµç ȯÀÚ¿¡¼­ PrP À¯ÀüÀÚÀÇ º¯À̸¦ È®ÀÎÇÒ ¼ö ÀÖ´Ù. ÇüÅÂÇÐÀû ¼Ò°ßÀº º¸Åë ½Ã»ó¿¡¼­¸¸ °üÂûµÇ´Âµ¥ ½Å°æ ¼¼Æ÷ÀÇ ¼Ò½Ç°ú ´õºÒ¾î ±³¼¼Æ÷°¡ Áõ½ÄÇϰí ÇØ¸é»ó º¯È­¸¦ º¸ÀδÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lipoprotein electrophoresis Electrophoretic separation of plasma lipoproteins.
(05 Mar 2000)
lipoprotein lipase <enzyme> An enzyme of the hydrolase class that catalyses the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinaemia type I.
Chemical name: Triacylglycero-protein acylhydrolase
Registry number: EC 3.1.1.34
(12 Dec 1998)
lipoprotein Lp(a) A lipoprotein composed of an LDL particle combined with an additional protein, Lp(a) specific protein; elevated levels have been identified as a risk factor for coronary artery disease.
(05 Mar 2000)
lipoprotein polymorphism Heritable variations in low density beta-lipoproteins; the variant lipoproteins exhibit different antigenic and chemical properties when compared with normal lipoproteins.
(05 Mar 2000)
lipoprotein-x An abnormal lipoprotein which is present in large amounts in individuals suffering from obstructive liver diseases. It exists as a bilayer vesicle of equimolar phospholipids and unesterified cholesterol containing small amounts of plasma proteins (mainly albumin) in its internal aqueous compartment together with some apolipoproteins adsorbed on its surface. Separates with ldl by ultracentrifugation.
(12 Dec 1998)
low density lipoprotein <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats in the bloodstream.
High levels of low density lipoprotein are considered a positive risk factor for the development of coronary artery disease. Less than 130 mg/dl is desirable, 130 to 159 mg/dl is borderline high, over 160 is considered high.
Acronym: LDL
(10 Jan 1998)
low density lipoprotein receptor <biochemistry> A cell surface protein that mediates the endocytosis of low density lipoprotein by cells.
Genetic defects in low density lipoprotein receptors lead to abnormal serum levels of low density lipoprotein and hypercholesterolaemia.
(16 Mar 1998)
low-density lipoprotein receptors Receptors on the surface of cells, especially liver cells, which bind to low density lipoprotein and promote clearance of LDL from the plasma.
(05 Mar 2000)
benign familial chorea A rare, nonprogressive movement disorder characterised by chorea and athetosis appearing in early childhood, most commonly manifested as gait ataxia and upper limb coordination. Intellect is unaffected. Probably autosomal-dominance inheritance with incomplete penetrance.
(05 Mar 2000)
benign familial chronic pemphigus Recurrent eruption of vesicles and bullae that become scaling and crusted lesions with vesicular borders, predominantly of the neck, groin, and axillary regions; autosomal dominant inheritance, presenting in late adolescence or early adult life.
Synonym: Hailey-Hailey disease.
(05 Mar 2000)
benign familial icterus Mild jaundice due to increased amounts of unconjugated bilirubin in the plasma without evidence of liver damage, biliary obstruction, or haemolysis; thought to be due to an inborn error of metabolism in which the excretion of bilirubin by the liver is defective, ascribed to decreased conjugation of bilirubin as a glucuronide or impaired uptake of hepatic bilirubin.
Synonym: benign familial icterus, constitutional hepatic dysfunction, Gilbert's disease, Gilbert's syndrome, Hebra's disease.
(05 Mar 2000)
cancer, breast, familial A number of factors have been identified that increase the risk of breast cancer. One of the strongest of these risk factors is the history of breast cancer in a relative. About 15-20% of women with breast cancer have such a family history of the disease, clearly reflecting the participation of inherited (genetic) components in the development of some breast cancers. Dominant breast cancer suceptibility genes, including BRCA1 and BRCA2, appear responsible for about 5% of all breast cancer.
(12 Dec 1998)
paralysis, familial periodic An autosomal dominant trait marked by recurring attacks of rapidly progressive flaccid paralysis. There are three types: I, associated with a fall in serum potassium levels (hypokalaemic periodic paralysis); II, associated with a rise therein (hyperkalaemic periodic paralysis, called also adynamia episodica hereditaria); and III, with normal levels (normokalaemic periodic paralysis).
(12 Dec 1998)
pemphigus, benign familial Rare hereditary disease characterised by recurrent eruptions of vesicles and bullae mainly on the neck, axillae, and groin. It exhibits autosomal dominant inheritance and is unrelated to pemphigus vulgaris though it closely resembles that disease.
(12 Dec 1998)
chronic familial icterus <haematology> A hereditary disorder that leads to a chronic haemolytic anaemia due to an abnormality in the red blood cell membrane.
This disorder is caused by a defective gene. Red cells are resistant to stress and rupture easily. Infants may appear jaundiced and pale. Fatigue, weakness and shortness of breath are other symptoms that may be seen in older patients. The spleen may also be enlarged.
Treatment includes splenectomy (removal of the spleen). After this is accomplished the life-span of the red blood cells returns to normal.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á